ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.
- If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.
- “AADC Deficiency is a devastating rare pediatric movement disorder that causes significant developmental delays and autonomic symptoms starting from birth.
- Patients with AADC deficiency are at a high risk of death in the first decade of life,” stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro.
- Through our partnership with PTC, we are demonstrating our commitment to drive progress for the AADC Deficiency community.”